Program
aflibercept
Also written as “Aflibercept”, “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)” and “aflibercept injection (VEGF Trap-Eye, BAY86-5321)”.
Its studies are mostly in Macular Degeneration · Macular Edema · Colorectal Neoplasms · Lymphoma, Non-Hodgkin · Retinal Vein Occlusion, led by 15 companies.
Drug pageAflibercept: every studyMany companies study it; this page follows only the 86 they lead. All 268 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regeneron Pharmaceuticalsits history only | 251 open or running | phase 4since Nov 2, 2012 | May 13, 2002 | none ahead |
| Bayerits history only | 230 open or running | phase 4since Apr 10, 2014 | Mar 12, 2008 | none ahead |
| Sanofiits history only | 200 open or running | phase 3since May 16, 2006 | Jan 30, 2006 | none ahead |
| Novartisits history only | 40 open or running | phase 4since Jul 22, 2016 | Jul 22, 2016 | none ahead |
| Amgen | 31 open or running | phase 3since Feb 13, 2020 | Feb 13, 2020 | Jul 31, 2027phase 3 · NCT07614776 |
| Sam Chun Dang Pharm.its history only | 20 open or running | phase 3since Jul 17, 2020 | Jul 17, 2020 | none ahead |
| AbbVieits history only | 11 open or running | phase 2since Mar 16, 2022 | Mar 16, 2022 | Jun 2031phase 2 · NCT05296447 |
| AO GENERIUMits history only | 11 open or running | phase 3since Sep 18, 2026 | Sep 18, 2026 | May 2028phase 3 · NCT07844148 |
| bioeq-gmbhits history only | 10 open or running | phase 3since Aug 11, 2020 | Aug 11, 2020 | none ahead |
| cinnagenits history only | 10 open or running | phase 3since Sep 18, 2022 | Sep 18, 2022 | none ahead |
| Exegenesis Bioits history only | 11 open or running | phase 1since Jan 30, 2025 | Jan 30, 2025 | Feb 2029phase 1 · NCT06817343 |
| formycon-agits history only | 10 open or running | phase 4since Nov 25, 2024 | Nov 25, 2024 | none ahead |
| Qilu Pharmaceuticalits history only | 10 open or running | phase 3since Apr 19, 2022 | Apr 19, 2022 | none ahead |
| Samsung Bioepisits history only | 10 open or running | phase 2since Sep 21, 2026 | Sep 21, 2026 | none ahead |
| the-emmes-company-llcits history only | 10 open or running | phase 3since Oct 22, 2013 | Oct 22, 2013 | none ahead |
Also a collaborator on its studies: REGENXBIO and Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Amgen only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Feb 13, 2020First study: phase 3 study in Macular DegenerationFirst studyNCT04270747 · 576 enrolled · United States, Canada, Czechia and more
- Jul 21, 2022Named afliberceptINNProposed as its International Nonproprietary Name in WHO's List 127
- Jan 20, 2023Phase 3 study in Chorioretinal Vascular DiseaseNCT05704725 · 49 enrolled · United States
- May 22, 2026Phase 3 study in Neovascular Age-related Macular DegenerationNCT07614776 · 304 planned · United States, Czechia, Hungary and more
Ahead
- Jul 31, 2027Primary completion: phase 3 study in Neovascular Age-related Macular DegenerationNCT07614776
TargetBeta
“Vascular endothelial growth factor A inhibitor; Placenta growth factor inhibitor”ChEMBL 37, by rule
Studies
All 3 Amgen leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07614776Neovascular Age-related Macular Degeneration · United States, Czechia, Hungary and more | 3 | Recruiting | Jul 31, 2027 | 304 |
| NCT05704725Chorioretinal Vascular Disease · United States | 3 | Completed | Feb 17, 2023 | 49 |
| NCT04270747Macular Degeneration · United States, Canada, Czechia and more | 3 | Completed | Jul 18, 2022 | 576 |
How it is read
Names in the registry
- “Aflibercept”, 9 entries
- “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)”, 8 entries
- “aflibercept injection (VEGF Trap-Eye, BAY86-5321)”, 8 entries
- “aflibercept”, 7 entries
- “Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)”, 7 entries
Codes read as this program: BAY865321, SCD411.
Conditions, from the studies’ own filings
- Macular Degeneration, 28 studies
- Macular Edema, 15 studies
- Colorectal Neoplasms, 8 studies
- Lymphoma, Non-Hodgkin, 5 studies
- Retinal Vein Occlusion, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.